Selective requirement of MYB for oncogenic hyperactivation of a translocated enhancer in leukemia

L Smeenk, S Ottema, R Mulet-Lazaro, A Ebert… - Cancer discovery, 2021 - AACR
In acute myeloid leukemia (AML) with inv (3)(q21; q26) or t (3; 3)(q21; q26), a translocated
GATA2 enhancer drives oncogenic expression of EVI1. We generated an EVI1-GFP AML …
被引用次数：29 相关文章
[HTML] nih.gov

[HTML][HTML] Selective requirement of MYB for oncogenic hyperactivation of a translocated enhancer in leukemia

L Smeenk, S Ottema, R Mulet-Lazaro, A Ebert… - Cancer …, 2021 - ncbi.nlm.nih.gov
In acute myeloid leukemia (AML) with inv (3)(q21; q26) or t (3; 3)(q21; q26), a translocated
GATA2 enhancer drives oncogenic expression of EVI1. We generated an EVI1-GFP AML …

Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.

L Smeenk, S Ottema, R Mulet-Lazaro, A Ebert… - Cancer …, 2021 - europepmc.org
In acute myeloid leukemia (AML) with inv (3)(q21; q26) or t (3; 3)(q21; q26), a translocated
GATA2 enhancer drives oncogenic expression of EVI1. We generated an EVI1-GFP AML …

Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia

L Smeenk, S Ottema, R Mulet-Lazaro… - Cancer …, 2021 - pubmed.ncbi.nlm.nih.gov
In acute myeloid leukemia (AML) with inv (3)(q21; q26) or t (3; 3)(q21; q26), a translocated
GATA2 enhancer drives oncogenic expression of EVI1. We generated an EVI1-GFP AML …

Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia.

L Smeenk, S Ottema, R Mulet-Lazaro, A Ebert… - Cancer …, 2021 - europepmc.org
In acute myeloid leukemia (AML) with inv (3)(q21; q26) or t (3; 3)(q21; q26), a translocated
GATA2 enhancer drives oncogenic expression of EVI1. We generated an EVI1-GFP AML …